Pregnancy of Taurcox in details
Taurcox has been assigned to a pregnancy category C by the FDA. There are no controlled data in human pregnancy. There are reports of ophthalmic abnormalities occurring in infants born to women on antituberculous therapy that included Taurcox. Taurcox should only be given during pregnancy when benefit outweighs risk.
Taurcox crosses the placenta. In one patient, maternal blood, placental blood and cord blood concentrations were 5.5, 5.0, and 4.1, respectively, immediately following delivery. No adverse effects were reported in the infant who had been exposed since 23 weeks gestation. Bobrowitz and colleagues studied 42 pregnancies which involved Taurcox exposure in addition to other antituberculous agents. The majority of these pregnancies were treated throughout gestation. No consistent pattern was noted in the reported fetal adverse effects, which included supernumerary nipple, small umbilical hernia, mild right tibial torsion, congenital dislocation of hips, left hydrocele, minimal metatarsus adductus, and skin tag on finger. Other reports also have not associated Taurcox with teratogenic effects. The initial therapy of active tuberculosis in pregnant patients recommended by the Centers for Disease Control and Prevention includes Taurcox. Taurcox is also recommended by the American Thoracic Society in cases of suspected drug-resistant tuberculosis.
See references
Taurcox breastfeeding
Taurcox is excreted into human milk. Taurcox is considered compatible with breast-feeding by the American Academy of Pediatrics.
See references
References for pregnancy information
- Bobrowitz ID "Taurcox in pregnancy." Chest 66 (1974): 20-4
- "Product Information. Myambutol (Taurcox)." Lederle Laboratories, Wayne, NJ.
- Lewit T, Nebel L, Terracina S, Karman S "Taurcox in pregnancy: observations on embryogenesis." Chest 66 (1974): 25-6
- CDC "Initial therapy for tuberculosis in the era of multidrug resistance. Recommendations of the advisory council for the elimintion of tuberculosis." MMWR Morb Mortal Wkly Rep 42 (1993): 1-8
- American Thoracic Society, Centers for Disease Control "Treatment of tuberculosis and tuberculosis infection in adults and children." Am Rev Respir Dis 134 (1986): 355-63
- Shneerson JM, Francis RS "Taurcox in pregnancy--foetal exposure." Tubercle 60 (1979): 167-9
- Holdiness MR "Transplacental pharmacokinetics of the antituberculosis drugs." Clin Pharmacokinet 13 (1987): 125-9
- Medchill MT, Gillum M "Diagnosis and management of tuberculosis during pregnancy." Obstet Gynecol Surv 44 (1989): 81-4
- Snider DE Jr, Layde PM, Johnson MW, Lyle MA "Treatment of tuberculosis during pregnancy." Am Rev Respir Dis 122 (1980): 65-79
References for breastfeeding information
- Snider DE, Powell KE "Should women taking antituberculosis drugs breast-feed?" Arch Intern Med 144 (1984): 589-90
- Committee on Drugs, 1992 to 1993 "The transfer of drugs and other chemicals into human milk." Pediatrics 93 (1994): 137-50
- "Product Information. Myambutol (Taurcox)." Lederle Laboratories, Wayne, NJ.
References
- DailyMed. "ETHAMBUTOL HYDROCHLORIDE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- PubMed Health. "Myambutol: This section provide the link out information of drugs collectetd in PubMed Health. ". http://www.ncbi.nlm.nih.gov/pubmedhe... (accessed September 17, 2018).
- Human Metabolome Database (HMDB). "Ethambutol: The Human Metabolome Database (HMDB) is a freely available electronic database containing detailed information about small molecule metabolites found in the human body.". http://www.hmdb.ca/metabolites/HMDB0... (accessed September 17, 2018).
Reviews
Consumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
